CLL: Exciting to Await the New Guidelines, Approved by Danish Authorities
Listen to Lisbeth Enggaards’ perspectives on CLL from the ASH 2023 meeting, mentioning the GAIA/CLL13 and GLOW studies. Enggaard discusses the uncertainty in the best treatment approaches with new drugs like BTK inhibitors, Bcl-2 inhibitors, and CD20 antibodies. She further expresses concern about the limitations set by Danish Authorities (Medicinrådet) on using these new treatments upfront.
